99861-96-8

Basic information

• Product Name: 1-Propanol, 2-methoxy-, 4-methylbenzenesulfonate
• CAS NO: 99861-96-8
• Molecular Formula: C11H16O4S
• Molecular Weight: 244.312
• Mol File: 99861-96-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-Propanol, 2-methoxy-, 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanol, 2-methoxy-, 4-methylbenzenesulfonate(99861-96-8)
• EPA Substance Registry System: 1-Propanol, 2-methoxy-, 4-methylbenzenesulfonate(99861-96-8)

Safety Data

• Hazardous Substances Data: 99861-96-8(Hazardous Substances Data)

Upstream product

• 1589-47-5 2-methoxypropanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 32464-98-5 toluene-4-sulfonic acid 2-hydroxypropyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 1079402-30-4 2-bromo-4-fluoro-1-(2-methoxypropoxy)-benzene 

Relevant articles and documents

SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES

Provided herein are pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

PYRAZOLOTHIAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.